Results 231 to 240 of about 85,660 (309)

Case Report: Cutaneous T-cell lymphoma associated with biologic therapy: three cases and a literature review. [PDF]

Front Med (Lausanne)
Li T, Wang G, Zhang C, Wang W, Li C, Wang Y.   +5 more
europepmc   +1 more source

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy

European Journal of Haematology, Volume 116, Issue 6, Page 771-784, June 2026.
ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

The notch sign as a clue for the diagnosis of early cutaneous T-cell lymphoma. [PDF]

JAAD Case Rep
Harkemanne E, Secco LP, Baeck M.
europepmc   +1 more source

Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study

International Journal of Cancer, Volume 158, Issue 10, Page 2581-2591, 15 May 2026.
What's New? Thin cutaneous malignant melanoma has an excellent ten‐year melanoma‐specific survival of 93%–97%. Moreover, the incidence of melanoma is higher among individuals with high socioeconomic status, which may protect them from other diseases. This nationwide matched cohort study found that patients with thin cutaneous malignant melanoma have a ...
Ylva Naeser, Rasmus Mikiver, Karolin Isaksson, Mats Lambe, Gustav J. Ullenhag   +4 more
wiley   +1 more source

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, Volume 20, Issue 5, Page 1299-1322, May 2026.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source

Olfactory receptors as tumor suppressors in cutaneous T-cell lymphoma via p38γ pathway modulation. [PDF]

Blood Neoplasia
Zhang XH, Li H, Hsiang J, Chen CH, Nam S, Wong H, Wu X, Hu W, Shively J, Rosen ST.   +9 more
europepmc   +1 more source

Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides

Advanced Science, Volume 13, Issue 26, 8 May 2026.
Single‐cell RNA analyses of paired lesions from CD30+ mycosis fungoides patients demonstrate that brentuximab vedotin (BV) induces immunogenic cell death in both CD30+ and CD30− malignant T cells. BV also targets regulatory T cells and remodels tumor microenvironment, while resistance is driven by impaired IFN responses, drug efflux, and BCL2 ...
Yi Jiang, Pan Lai, Mingjia Li, Yujie Wen, Mengzhou Cao, Yu Xiao, Zhuojing Chen, Jingru Sun, Yang Wang   +8 more
wiley   +1 more source

Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma. [PDF]

Blood Adv
Querfeld C, Palmer J, Han Z, Wu X, Yuan YC, Chen MH, Su C, Tsai NC, Smith DL, Hammond SN, Crisan L, Song JY, Pillai R, Rosen ST, Zain J.   +14 more
europepmc   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

Advanced Science, Volume 13, Issue 25, 4 May 2026.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen, Yang Yu, Xiutao Cai, Junhao Lin, Ruirui Liang, Rui Kang, Daolin Tang, Jiao Liu   +7 more
wiley   +1 more source

Unveiling the Role of the Cellular Tumor Microenvironment and the Therapeutic Targets it Provides in Cutaneous T-Cell Lymphoma. [PDF]

Curr Oncol Rep
Chinas NA, Kaliampou S, Nikolaou V.
europepmc   +1 more source